A hallmark of medical decision-making is the ability to predict accurately treatment outcomes. Studies that determine prognostic variables for any medical therapy are critical in assessing the risks and benefits of a potential procedure. Over the past several decades, many investigators have published reports of predictive variables influencing outcomes in bone marrow transplantation (BMT). Such investigative studies are often confounded by the fact that many variables exist in BMT: from a wide array of diseases, and disease stages, to many potential toxicities from the transplant itself. Nevertheless, accurate prognostic variables concerning outcomes of BMTs are vital for informed decision-making for both physicians and patients.
This review will briefly summarize variables, both pre and post transplant, predictive of myeloablative BMT outcome, and will also review variables influencing the development of graft-versus-host disease (GVHD) in allogeneic transplantation. This report will not summarize predictive variables focusing specifically on toxicities of transplantation, such as veno-occlusive disease of the liver and hemorrhagic cystitis, and will not include diseasespecific prognostic items, such as karyotype in leukemia. Finally, predictive factors for nonmyeloablative transplants are only beginning to be discovered and will not be covered in this review.
Age
Historically, age is frequently cited as an important prognostic variable in BMT. Indeed, many investigative protocols have an upper age limit for patient enrollment. Such age cutoffs have historically been at 55, 60, or 65 years of age. The rationale for the age cutoff is presumably that the transplant procedure is prohibitively risky in patients older than the listed age cutoff. Common transplant teaching suggests that the older the patient, the higher the risk of GVHD and treatment-related mortality (TRM), resulting in older patients having decreased disease-free survival (DFS). Most of the literature examining the influence of age on BMT outcome, however, is limited by several factors. First, many of the early reports are combined adult and pediatric patient populations, which result in studies comparing transplant outcomes of adults vs pediatric patients. Second, many studies of the influence of age on autologous stem cell transplant (ABMT) were published prior to the routine use of peripheral blood progenitor cells (PBPCs) as the source of hematopoietic cells for marrow reconstitution. The use of PBPCs has significantly reduced many of the risks involved in ABMT. Tables 1 and 2 show a representation of studies reporting the influence of age on outcome of allogeneic BMT (allo-BMT) for AML (Table 1) and ALL/CML (Table 2) . These tables represent a collection of the largest published series on the topic; they are not intended to list every published report concerning the influence of age on BMT in the world's literature. The first thing to note is that the data are conflicting. Some reports find that survival is better in younger patients, and some find no influence of survival based on patient age. The second point is that most of these reports have an extensive pediatric population, with a median age of patients in the study that is quite young (median age (years) 23, 26, 22, etc) . Thus, some studies reporting an improved DFS in younger patients do so because the younger patients are pediatric patients. While certainly it may be true that adults have a higher risk of TRM as compared to pediatric patients, the real question concerning age and allo-BMT is whether there is an age cutoff above which the procedure is prohibitively risky. Few, if any, of these studies adequately addresses this point. Finally, no study found an association of the risk of leukemic relapse post transplant with age.
There have been a handful of published reports specifically investigating BMT outcome in older adults, as shown in Table 3 . No study has shown an influence in age with the risk of leukemic relapse post transplant. Most of these studies find no significant difference in transplant outcome comparing older adults (usually defined as 440 years of age, or 450 years of age) with overall outcome. 96 Single institution review; unrelated allo-BMT, age 440 years compared to younger adults (median age 23 years); trend towards TRM in older pts but similar 3-year OS Pts, patients; IBMTR, International Bone Marrow Transplant Registry; EBMT, European Bone Marrow Transplant Registry; PFS, progression-free survival; OS, overall survival; TRM, treatment-related mortality; EFS, event-free survival; DFS, disease-free survival.
Are predictive factors clinically useful in BMT?
Several studies have shown a trend towards increased TRM in patients over the age of 45 or 50 years; however, no study concluded that defined age cutoff exists at which the risks of the transplant are prohibitive. Table 4 summarizes studies investigating influence of age on outcome of autologous transplantation. Again, some studies report an increase in TRM in older adults compared to younger adults, whereas others do not. Additionally, data are conflicting with respect to the influence of age on overall survival (OS). The largest series, an ABMTR analysis of the influence of age in NHL or breast cancer, found no influence of age on OS or TRM. 26 In summary, age is a poor predictor of BMT outcome in both allogeneic and autologous transplantation. Pediatric patients may have a better outcome when compared to adults. Older adults may have a somewhat higher risk of transplant-related mortality than do younger adults. However, no study has definitively established a chronologic age at which the risk of the transplant is prohibitive.
Graft-versus-host disease
While the most important risk factor is the development of GVHD after allo-BMT is the degree of HLA matching, other variables have been reported to influence the development of both acute GVHD (aGVHD) and chronic GVHD (cGVHD). Some of these reports are summarized in Table 5 . It is common teaching to say that increasing age influences the risk of GVHD. However, in a similar matter to the issue of the influence of age on OS, much of these data compares pediatric patients to adult patients. When studies have a median population age of 20-25 years, the issue of age becomes one of comparing the outcomes of adult vs pediatric patients. Most Table 4 Influence of age on outcome of auto-BMT data, indeed, suggest that adults have a higher risk of development of both aGVHD and cGVHD than do children. No study, however, has definitively established an age limit at which the risk of GVHD is prohibitive. The other variable that is consistently mentioned as predictive of aGVHD is sex-mismatched donor-recipient pairs, specifically female donors infused into male recipients. This association may not exist if the female donor is nulliparous. Prior aGVHD is also a clear risk factor for the development of cGVHD.
More recently, the use of PBPCs has become embraced by many in the allo-BMT community as a preferred source of donor cells primarily because of faster engraftment and potentially reduced TRM. 36, 37 Most data comparing allogeneic PBPCs with allogeneic marrow do not find an influence of PBPCs on the development of acute GVHD. [36] [37] [38] Some studies, however, do find an increased incidence in the development of cGVHD, both in incidence and severity, with the use of allogeneic PBPCs. [39] [40] [41] [42] [43] [44] [45] [46] Most of the reported studies do not have long-term follow-up. This fact is crucial, since the ultimate morbidity and mortality of cGVHD requires years of follow-up. Given the limited follow-up in many of the reported series comparing allogeneic bone marrow with allogeneic PBPCs, the ultimate benefit of the two sources of hematopoietic cells may not yet be known.
In summary, factors that may influence the development of aGVHD are increasing age (although no data suggest an absolute age limit for allo-BMT) and female donors. PBPCs may lead to more and more extensive cGVHD.
Pre BMT cardiopulmonary evaluation
Part of a routine pre BMT work up involves an assessment of cardiopulmonary status of the transplant recipient. Generally, patients have an assessment of their left ventricular ejection fraction (LVEF) with either a radionucleotide (MUGA) scan or an echocardiogram. Pulmonary status is assessed with standard pulmonary function testing (PFT) with an assessment of diffusing capacity (DLCO). The rationale for such testing is that the BMT procedure may be quite stressful, and patients with compromised cardiac or pulmonary status are at higher risk of TRM. Most BMT protocols have LVEF and PFT eligibility criteria; patients with poor LVEF or PFT results are routinely excluded from study entry. However, there are relatively few reports that specifically address the clinical utility of such pre transplant testing. These reports are summarized in Table 6 . The series that examine the value of pre transplant cardiac evaluation do not find compelling evidence of their predictive value. One study extensively evaluated patients with exercise tolerance testing (ETT). Unfortunately, the results of the ETT had no predictive value with respect to TRM, 49 in contrast to an earlier report. 47 The other large series also found no predictive value of pretransplant cardiac evaluation. 48 One positive study is difficult to evaluate because of three patients who developed post transplant congestive heart failure, two had a normal pre transplant LVEF of 55%. 51 We have examined TRM in 308 consecutive NHL or HD patients receiving an ABMT from 12 February 1996 to 30 January 2003 at the Cleveland Clinic Foundation in patients with an LVEF (measured by echocardiography) 383 Single institution review of auto and allo pts; multivariate analysis of pre BMT factors found the following associated with m 100-day mortality: allo vs auto; k FEV 1 ; m creatinine; m bilirubin; and k performance status Pts, patients; PFS, progression-free survival; OS, overall survival; TRM, treatment-related mortality; EFS, event-free survival; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; PFT, pulmonary function testing.
greater than 50% (n ¼ 288) vs those with an LVEF o50% (n ¼ 202; four, 30-40% and 16, 40-50%). There was no difference in early TRM between the two groups. The 5-year OS was the same in both groups. In contrast, it appears that abnormal PFT does have predictive value with respect to TRM. Both an abnormal DLCO and an abnormal FEV 1 have been described to be associated with both an increased risk of TRM and an increased risk in post transplant cytomegalovirus infection. 50, 51 However, no study has adequately assessed what level of pulmonary compromise makes the risks of an autologous BMT (auto-BMT) or allo-BMT untenable.
The issue of pre BMT cardiopulmonary evaluation is problematic. BMT is known to be associated with potential cardiac and pulmonary toxicities. [56] [57] [58] [59] It is intuitive to believe that TRM would be influenced by abnormal cardiopulmonary function. Adequate cardiac function is required to handle the large amounts of fluids that are used in conjunction with high-dose chemotherapy. Normal pulmonary function should help to withstand the rigors of infection and other pulmonary insults. Unfortunately, however, no data exist that adequately address the absolute minimum cardiopulmonary function required for a patient to be eligible for a BMT. Most patients undergoing an ablative allo-BMT have an underlying malignancy that will likely be otherwise fatal. In the absence of any literature defining minimum criteria of cardiopulmonary function, it may be difficult to deny the curative potential of a BMT to a patient with less than optimal cardiopulmonary reserve. The entire area of pre BMT assessment and eligibility for BMT protocols is an excellent example of an area of transplantation in need of renewed clinical research.
Post allo-BMT prognostic variables
Most literature addressing BMT prognostic variables investigate pre-transplant parameters. However, many studies have examined clinical variables that occur early post transplantation which influence long-term outcome. The significant majority of these data have occurred in allo-BMT, and are summarized in Table 7 .
Several points are of interest. A series published over a decade ago defines the utility of 'screening studies' performed 100 days post allo-BMT. The rationale was that a random skin or mucosal biopsy that predicted the development of later cGVHD might influence patient management. Indeed, the study found that a positive skin biopsy (that in the absence of clinical GVHD) showing histologic changes consistent with GVHD was predictive for the development of later cGVHD. 55 This has lead to the widespread use of a variety of screening studies performed at day þ 100. Unfortunately, a subsequent series from the same institution did not support the routine use of any Table 7 Post allo-BMT clinically predictive variables Single institution pediatric review; pts with platelet count o100 000/ml for 120 days post transplant had k survival, and m incidence of severe aGVHD and cGVHD Sullivan et al 64 
1988
164 Single institution prospective trial of cGVHD therapy; pts with extensive cGVHD and platelet counts o100 000/ml had m nonrelapse mortality as those with higher platelet counts Przepiorka et al 65 
2001
116 Single institution review of allo stem cell transplant pts surviving at least 100 days; cGVHD pts with platelet count o100 000/ml had m overall mortality and m treatment failure at 18 months post BMT Wagner et al 107 Single institution review of allo-BMT pts surviving at least 100 days analyzed by day+100 platelet count; the 4-year survivals for those with platelet counts 450, 30-50, and o30 were 76, 39, and 13.5%, respectively (Po0.001). Causes of death were also different: of those with platelet count o50, 68% died of TRM vs only 20% with count 450 (P ¼ 0.005)
Miscellaneous
Bacigalupo et al particular screening study performed at day þ 100. 56 The variables reported in the more recent study that were predictive of cGVHD were prior GVHD and advanced age. Therefore, it is difficult to advocate routine blind skin or buccal mucosa biopsies at day 100 to predict for cGVHD.
In contrast, however, many studies have shown that thrombocytopenia is an adverse prognostic variable after allo-BMT. Some of the studies have used platelet count of 100 000/ml as a cutoff, in which patients with a platelet count less than 100 000/ml have a worse prognosis than do patients with a more normal platelet count. One recently reported study found a dramatic correlation of 4-year OS with the platelet count on day þ 100 post transplant: 4-year OS for those with platelet counts 450, 30-50, and less than 30 were 76, 39, and 13.5%, respectively (Po0.001). 61 Additionally, causes of death were different in the two treatment groups: for those with a platelet count less than 50, 68% died of TRM vs only 20% with a platelet count 450 (P ¼ 0.005). The reason for this association is somewhat conjectural. Thrombocytopenia may be a surrogate marker for the severity of cGVHD, a marker for diminished graft function, or a marker for a subclinical infectious disease complications. There are other potential variables that may influence a platelet count after allo-BMT. Nevertheless, the measurement of a platelet count at day þ 100 is an extremely simple test that seems to be a powerful predictor of ultimate transplant outcome.
Two recently reported studies have shown that clinical and biochemical variables performed only 7 days post transplant may be predictive of TRM. One study found that day þ 7 serum bilirubin and BUN levels were accurate predictors of TRM in 309 patients receiving an allo-BMT. 62 A more recently reported study found that day þ 7 variables predictive of TRM in allo-BMT recipients included the absence of fever, elevated alkaline phosphatase, elevated BUN, elevated creatinine, elevated bilirubin, thrombocytopenia and leukopenia. 63 While provocative, one might certainly argue that the day þ 7 parameters described above are surrogate markers for either the severity of the underlying malignancy pre transplant or the overall health of the patient going into the transplant, or both. Nevertheless, day þ 7 easily measured clinical variables that might influence TRM have potential clinical importance in monitoring patients during the peritransplant process. Potentially, more aggressive interventions might be instituted should adverse factors develop.
Other variables have been described to influence BMT outcome. One series reported that patients weighing less than their ideal weight at the time of BMT have an inferior overall outcome. 70 The Mayo Clinic has reported that early lymphocyte recovery after auto-BMT is associated with improved survival in breast cancer, multiple myeloma, and non-Hodgkin's lymphoma. 71, 72 Faster lymphocyte recovery has also reported to correlate with better survival in allo-BMT. 73 One group reported that an increase in serum levels of C-reactive protein is a risk factor for the occurrence of treatment-related complications after allo-BMT. 74 Finally, two studies suggest the possibility of psychosocial factors influencing outcome after stem cell transplantation. A study of 193 patients found that patients who were depressed post BMT (auto or allo) had a three-fold risk of dying than did nondepressed patients. 75 The measurement of depression occurred 6 and 12 months post transplant. Another study described a strong association of survival after allo-BMT based on the presence or absence of a caregiver. Patients with a lay care partner present with them during the initial in-patient stay after an ablative allogeneic transplant had a significantly better OS than did those without a lay care partner. 76 These studies suggesting the possibility that psychosocial variables may have a bearing in survival outcome after BMT are intriguing and worthy of continued study.
Summary
Unfortunately, most of the published literature concerning predictive parameters in BMT is somewhat limited. Advanced age may contribute to a higher risk of GVHD and TRM, but no study has established an age criteria at which a patient should be denied the curative potential of a BMT. Pre transplant cardiopulmonary evaluations are important tools to assess the overall health of a given patient, but only serve as guides to help assess the risk/ benefit ratio of performing a transplant. Pulmonary testing may be more valuable than cardiac testing. The value of random skin or mucosal biopsies at day þ 100 after allo-BMT is limited at best. More recently reported studies of clinical variables affecting outcome after allo-BMT may be more clinically useful, and may correlate with ultimate outcome. Psychosocial variables may also influence outcome.
The final message from this review is that the entire field of predictive factors in BMT requires renewed clinical investigation to define accurately pre and post transplant parameters that are clinically important. Ethical medical decision-making involves accurate measurement of risks and benefits. Ongoing clinical investigative research builds our knowledge base, and allows for the rationale and ethical use of BMT for our patients. This is an excellent time to embellish our knowledge of prognostic variables in BMT.
